Non Exudative AMD Imaged With SS-OCT

Study Overview
=================
Brief Summary
-----------------
The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.

Detailed Description
-----------------
This is a longitudinal observational study where the investigators will look at 450 subjects, 200 with intermediate AMD in at least one eye, or with AMD in one eye, either early or intermediate, and with late AMD (exudative) in the other eye, and 250 subjects with nGA or GA in at least one eye.

Official Title
-----------------
Non Exudative Age-Related Macular Degeneration Imaged With Swept Source Optical Coherence Tomography

Conditions
-----------------
Dry Macular Degeneration

Intervention / Treatment
-----------------
* Device: SS-OCT imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 50 and over Clinic diagnosis of non-exudative iAMD in at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02 mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR Clinical diagnosis of early or early/intermediate stage AMD in one eye in the absence of nGA or GA and exudative AMD in the other eye OR clinical diagnosis of GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye which has never been treated with anti-VEGF agents Willing and able to comply with clinic visits and study-related procedures Provide signed informed consent Exclusion Criteria: A subject who meets any of the following criteria will be excluded from the study: Below the age of 50 Subjects with exudative AMD in both eyes Eyes with evidence of non-proliferative and proliferative diabetic retinopathy. Presence of confounding ocular diagnosis such as myopia >6D, or other ocular conditions that may cause retinal pigment epithelium atrophy or exudative MNV Subjects unable to give informed consent. Subjects who are unable to comply with imaging guidelines

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1 'IMPACT Cohort'<br>Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years | Device: SS-OCT imaging<br>* All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument<br>* Other names: Optical Coherence Tomography Angiography;|
| Cohort 2 'SWAGGER Cohort'<br>Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years | Device: SS-OCT imaging<br>* All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument<br>* Other names: Optical Coherence Tomography Angiography;|
| Cohort 3<br>Subjects with GA enrolled in another trial | Device: SS-OCT imaging<br>* All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument<br>* Other names: Optical Coherence Tomography Angiography;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Choroidal Perfusion Deficits at 1 year compared to Baseline | Assessment of Choriocapillaris perfusion | 1 year time point | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pre-existing sub-clinical Macular Neovascularization (MNV) | Presence of abnormal new vessels arising from the Choroid | 1 year and 2-year time points | 
| Automated Drusen Volume measurements | Compare the automated measurements of drusen volume using the Zeiss algorithm with manual measurements by trained readers | 1 year and 2-year time points | 
| Automated GA measurements | Compare the automated measurements of GA area using the Zeiss algorithm with manual measurements by trained readers | 1 year and 2-year time points | 
| Structural OCT markers and Genetic Markers | Correlate structural markers on SS-OCT/OCTA with genetic markers of disease | 1 year and 2-year time points | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, early AMD, intermediate AMD, Geographic Atrophy, nascent GA